VivoSim Labs Inc. (VIVS)
VIVS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1497253/000119312526303316/0001193125-26-303316-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-03-31.
Profile
| Field | Value |
|---|---|
| Ticker | VIVS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001497253 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $131K |
| Net income | -$13.8M |
| Operating income | -$11.5M |
| Net margin | -10567.2% |
| Operating margin | -8768.7% |
| Revenue growth | -9.0% |
| Cash | $5.0M |
| Total assets | $7.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 19.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The Company has concluded that the prevailing conditions and ongoing liquidity risks faced by the Company raise substantial doubt about its ability to continue as a going concern for at least one year following the date these condensed consolidated financial statements are issued." | 10-Q 2026-11-12 |
| Cash and burn | $8.6M cash; operating cash flow -$2.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 20,281,495 (2026-11-01); 2,607,962 a year earlier; 8,837,095 three years earlier. 3y figure adjusted for splits (1-for-12 overall). | Cover page 2026-11-01 |
| Reverse splits, 3 years | 1; latest 1-for-12 on 2025-03-21 | Source 2025-03-21 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-08-21 |
| Auditor | Rosenberg Rich Baker Berman, P.A., Somerset, New Jersey, United States | PCAOB Form AP 2026-07-23 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-06-29 |
| Insider trades, 12 months | Bought $3K, sold $7K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2027 2026-09-30 | $51K | -$475K | -$2.5M | $8.6M | No debt tags | $135K | 10-Q 2026-11-12 |
| Q1 2027 2026-06-30 | $18K | -$1.3M | -$3.2M | $1.7M | No debt tags | $112K | 10-Q 2026-08-12 |
| Q4 2026 2026-03-31 | $40K | -$5.8M | -$2.2M | $5.0M | No debt tags | $131K | 10-K 2026-07-14 |
| Q3 2026 2025-12-31 | $26K | -$2.7M | -$2.3M | $4.3M | No debt tags | $142K | 10-Q 2026-02-11 |
| Q2 2026 2025-09-30 | $28K | -$2.5M | -$2.4M | $6.7M | No debt tags | $140K | 10-Q 2026-11-12 |
| Q1 2026 2025-06-30 | $37K | -$2.8M | -$3.9M | $9.1M | No debt tags | $142K | 10-Q 2026-08-12 |
| Q4 2025 2025-03-31 | $51K | $6.9M | -$2.0M | $11.3M | No debt tags | $144K | 10-K 2026-07-14 |
| Q3 2025 2024-12-31 | $24K | -$3.4M | -$1.8M | $1.2M | No debt tags | $122K | 10-Q 2026-02-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1 | 2026-07-31 |
| Latest annual report | 10-K | 2026-07-14 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-10-16 |
| Latest proxy | DEF 14A | 2026-08-21 |
Source: SEC EDGAR submissions feed, 820 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.1% |
| 1 month | -23.5% |
| 3 months | -60.6% |
| Year to date | -92.8% |
| 1 year | -93.9% |
| From 52-week high | -95.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CLDI | Calidi Biotherapeutics Inc. | $0.6023 | -3.15% | $2.2M |
| CELZ | Creative Medical Technology Holdings Inc. | $0.5201 | -1.51% | $4.0M |
| LIMN | Liminatus Pharma Inc. | $2.97 | -0.67% | $4.0M |
| CRIS | Curis Inc. | $0.4358 | -2.07% | $4.1M |
| BTTC | Black Titan Corporation | $0.2873 | -9.20% | $4.3M |
| AIM | AIM ImmunoTech Inc. | $0.1310 | -8.77% | $5.2M |
| SNTI | Senti Biosciences Holdings Inc. | $0.1360 | -2.86% | $5.2M |
| SLXN | Silexion Therapeutics Corp | $1.76 | -11.11% | $1.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier